Abstract
Insufficient infiltration or dysfunction of lymphocytes in the tumor immune microenvironment is considered to be a contributing factor to poor immunotherapy outcomes in solid tumors. Necroptosis, a form of immunogenic cell death, has attracted increasing interest because of its unique role in regulating tumor immune responses. CL-387785, a third-generation EGFR inhibitor, has been reported to inhibit tumors by regulating the cell cycle and inducing apoptosis; however, the underlying mechanisms remain unclear. In this study, we demonstrated that CL-387785 effectively suppressed the malignant phenotype of melanoma and lung cancer and confirmed that cancer cells undergo necroptosis, as evidenced by morphological and protein-level analyses. Further in vivo and in vitro experiments revealed that CL-387785 enhances tumor cell killing by immune cells by inducing CD80 expression on the tumor cell surface, thereby increasing CD8<sup>+</sup> T lymphocyte function. Detailed mechanistic studies indicated that CL-387785 targets TRADD, recruiting RIPK1 to induce necroptosis in tumor cells, with subsequent nuclear translocation of NF-κB, which regulates CD80 transcription. In conclusion, our findings indicate that CL-387785 induces necroptosis in tumor cells via the TRADD/RIPK1/NF-κB/CD80 signaling pathway, thereby sensitizing tumors to anti-PD-1 therapy. These results suggest that CL-387785 is a promising candidate for increasing tumor immunotherapy efficacy.
Introduction
The clinical success of immune checkpoint inhibitors (ICIs), such as anti-PD-1 antibodies, has been transformative for cancer therapy. However, a significant proportion of patients with solid tumors fail to respond due to an immunosuppressive tumor immune microenvironment (TME). These "cold" tumors often lack sufficient infiltration of functional CD8+ T cells. One promising strategy to overcome this resistance is the induction of Immunogenic Cell Death (ICD), which releases inflammatory signals that recruit and activate the immune system. Necroptosis, a regulated form of necrotic cell death, is a potent driver of ICD. This study investigates CL-387785, a small-molecule inhibitor, and its ability to trigger necroptosis and sensitize tumors to immunotherapy.
Methods
The researchers evaluated the anti-tumor activity of CL-387785 in human melanoma (SK-MEL-5, A375) and lung cancer (A549, H1299) cell lines. Cell viability was assessed using OD450nm measurements and colony formation assays. Cell cycle distribution was analyzed via flow cytometry. To characterize the mode of cell death, transmission electron microscopy (TEM) was used to observe morphological changes, and Western blotting was performed to detect phosphorylated RIPK1 and MLKL. Mechanistic pathways were explored using pull-down assays, shRNA knockdown, and Chromatin Immunoprecipitation (ChIP). In vivo efficacy was tested in a syngeneic B16-F10 melanoma mouse model, combining CL-387785 (25 mg/kg) with anti-PD-1 antibodies. Clinical correlations were derived from TCGA and other public patient datasets, including the Hwang (2020) and Kim (2019) cohorts.
Results
CL-387785 Inhibits Proliferation and Malignant Phenotypes In Vitro
CL-387785 demonstrated potent cytotoxicity across all tested cell lines, with IC50 values ranging from approximately 0.7 μM to 3.3 μM. Growth curves showed a clear dose-dependent inhibition of proliferation over 72 hours. Furthermore, the drug significantly suppressed the colony-forming ability of cancer cells and induced shifts in the cell cycle, particularly in the G0/G1 phase (Figure 1).
Induction of Necroptosis via TRADD/RIPK1 Signaling
Morphological examination by TEM revealed classic necroptotic features, such as plasma membrane rupture and organelle swelling. Biochemical analysis confirmed the activation of the necroptotic machinery, evidenced by increased levels of p-RIPK1 and p-MLKL. The study identified the adaptor protein TRADD as the direct target of CL-387785. Binding to TRADD facilitates the recruitment of RIPK1, initiating the necroptotic cascade independently of the drug's EGFR inhibitory activity.
CD80 Upregulation and Enhanced T Cell Function
A critical discovery was the upregulation of the costimulatory molecule CD80 on the surface of tumor cells undergoing CL-387785-induced necroptosis. This upregulation is driven by the NF-κB pathway; specifically, the p65 subunit translocates to the nucleus and binds to the CD80 promoter. Increased CD80 expression provides the necessary "second signal" for CD8+ T cell activation, significantly enhancing their cytotoxic potential against tumor cells.
Synergistic Anti-Tumor Effects In Vivo
In a B16-F10 melanoma mouse model, the combination of CL-387785 and anti-PD-1 therapy significantly slowed tumor growth compared to either treatment alone. While the total number of infiltrating CD8+ T cells remained relatively stable, the combination therapy dramatically increased the proportion of functional, Granzyme B-positive (GZMB+) T cells, which rose from ~3% in control groups to 18.5%. Clinical data analysis further validated these findings, showing that high CD80 expression is a positive predictor for anti-PD-1 therapy response and progression-free survival in cancer patients.
Discussion
This research highlights the potential of targeting necroptosis to overcome immunotherapy resistance. CL-387785 acts as a dual-action agent: it directly induces immunogenic cell death and actively remodels the tumor surface to express CD80. This "hot" TME then becomes highly susceptible to checkpoint blockade. The identification of the TRADD/RIPK1/NF-κB/CD80 axis provides a clear mechanistic rationale for this synergy. Future work should explore this combination in a wider variety of solid tumor models and optimize dosing for clinical translation.
Conclusion
CL-387785 effectively sensitizes melanoma and lung cancer to anti-PD-1 immunotherapy by inducing necroptosis and upregulating CD80. These findings support the development of necroptosis inducers as a viable strategy to enhance the efficacy of current immunotherapeutic regimens in solid tumors.
Summary updated